{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:39:38Z","timestamp":1792539578565,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adalimumab monotherapy for hidradenitis suppurativa (HS) is often insufficient with a maximum clinical efficacy of 60% in Hidradenitis Suppurativa Clinical Response (HiSCR) and limited effect on draining tunnels. Data suggest that adalimumab therapy could be improved by concomitant antibiotics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the clinical effectiveness of adalimumab with clindamycin and rifampicin versus adalimumab monotherapy after 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included patients who started adalimumab with additional clindamycin and rifampicin and patients treated with adalimumab monotherapy, matched on sex and refined Hurley score. The primary outcome measure was the difference in change in the International Hidradenitis Suppurativa Severity Score System (IHS4) at 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 62 patients were included in the combination therapy group (<jats:italic>n<\/jats:italic>\u2009=\u200931) and adalimumab monotherapy group (<jats:italic>n<\/jats:italic>\u2009=\u200931), showing comparable IHS4 scores; 32.5 versus 29, <jats:italic>p<\/jats:italic>\u2009=\u20090.87 at baseline respectively. The combination therapy demonstrated greater clinical effectiveness expressed in median IHS4 improvement (\u221220 vs. \u22129, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), IHS4\u201055 (74% vs. 36%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), median draining tunnel reduction (\u22124 vs. \u22122, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and pain response (47% vs. 27%, <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab initiated with clindamycin and rifampicin shows greater clinical effectiveness than adalimumab monotherapy. An important difference in effect was observed in the decrease of draining tunnels, addressing a serious limitation of adalimumab monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19725","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:42:43Z","timestamp":1702989763000},"page":"904-909","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9366-146X","authenticated-orcid":false,"given":"P.","family":"Aarts","sequence":"first","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Center  Rotterdam The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"van Huijstee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Center  Rotterdam The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H.","family":"van der Zee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Center  Rotterdam The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-3814","authenticated-orcid":false,"given":"K. R.","family":"van Straalen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Center  Rotterdam The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. P.","family":"Prens","sequence":"additional","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Center  Rotterdam The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02965"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14448"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17598"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17551"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","unstructured":"KokolakisG MartorellA KerdelF BettoliV Giamarellos\u2010BourboulisEJ SinclairR et\u00a0al.Secukinumab and concomitant antibiotic use in patients with moderate to severe hidradenitis suppurativa: week 16 efficacy and safety results from the phase 3 SUNSHINE and SUNRISE trials. Poster AAD. 2023.","DOI":"10.1016\/j.jaad.2023.07.345"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.5070\/D3226031313","article-title":"Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system","volume":"22","author":"Scheinfeld N","year":"2016","journal-title":"Dermatol Online J"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.089"},{"key":"e_1_2_12_14_1","first-page":"15","article-title":"A review of the anti\u2010inflammatory properties of clindamycin in the treatment of acne vulgaris","volume":"85","author":"Del Rosso JQ","year":"2010","journal-title":"Cutis"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2513"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.034"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18632"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15183"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000228337"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2021.33.6.515"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12792"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:34:31Z","timestamp":1714041271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/jdv.19725"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19725","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"2023-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}